Publikation:

How an inhibitor of the HIV-I protease modulates proteasome activity

Lade...
Vorschaubild

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

1999

Autor:innen

Holzhütter, Hermann-Georg
Bogyo, Matthew
Kairies, Norman
Groll, Michael
Giuli, Rita de
Emch, Sabine

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Journal of Biological Chemistry. 1999, 274(50), pp. 35734-35740. ISSN 0021-9258. eISSN 1083-351X. Available under: doi: 10.1074/jbc.274.50.35734

Zusammenfassung

The human immunodeficiency virus, type I protease inhibitor Ritonavir has been used successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may exert a direct effect on the immune system unrelated to inhibition of the human immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major histocompatibility complex class I restricted presentation of several viral antigens at therapeutically relevant concentrations (5 microM). In search of a molecular target we found that Ritonavir inhibited the chymotrypsin-like activity of the proteasome whereas the tryptic activity was enhanced. In this study we kinetically analyzed how Ritonavir modulates proteasome activity and what consequences this has on cellular functions of the proteasome. Ritonavir is a reversible effector of proteasome activity that protected the subunits MB-1 (X) and/or LMP7 from covalent active site modification with the vinyl sulfone inhibitor(125)I-NLVS, suggesting that they are the prime targets for competitive inhibition by Ritonavir. At low concentrations of Ritonavir (5 microM) cells were more sensitive to canavanine but proliferated normally whereas at higher concentrations (50 microM) protein degradation was affected, and the cell cycle was arrested in the G(1)/S phase. Ritonavir thus modulates antigen processing at concentrations at which vital cellular functions of the proteasome are not yet severely impeded. Proteasome modulators may hence qualify as therapeutics for the control of the cytotoxic immune response.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690SCHMIDTKE, Gunter, Hermann-Georg HOLZHÜTTER, Matthew BOGYO, Norman KAIRIES, Michael GROLL, Rita de GIULI, Sabine EMCH, Marcus GRÖTTRUP, 1999. How an inhibitor of the HIV-I protease modulates proteasome activity. In: Journal of Biological Chemistry. 1999, 274(50), pp. 35734-35740. ISSN 0021-9258. eISSN 1083-351X. Available under: doi: 10.1074/jbc.274.50.35734
BibTex
@article{Schmidtke1999inhib-22236,
  year={1999},
  doi={10.1074/jbc.274.50.35734},
  title={How an inhibitor of the HIV-I protease modulates proteasome activity},
  number={50},
  volume={274},
  issn={0021-9258},
  journal={Journal of Biological Chemistry},
  pages={35734--35740},
  author={Schmidtke, Gunter and Holzhütter, Hermann-Georg and Bogyo, Matthew and Kairies, Norman and Groll, Michael and Giuli, Rita de and Emch, Sabine and Gröttrup, Marcus}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/22236">
    <dc:creator>Holzhütter, Hermann-Georg</dc:creator>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:contributor>Kairies, Norman</dc:contributor>
    <dc:creator>Emch, Sabine</dc:creator>
    <dc:contributor>Groll, Michael</dc:contributor>
    <dc:creator>Bogyo, Matthew</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Giuli, Rita de</dc:creator>
    <dcterms:issued>1999</dcterms:issued>
    <dc:contributor>Bogyo, Matthew</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Kairies, Norman</dc:creator>
    <dc:contributor>Emch, Sabine</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Schmidtke, Gunter</dc:creator>
    <dcterms:abstract xml:lang="eng">The human immunodeficiency virus, type I protease inhibitor Ritonavir has been used successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may exert a direct effect on the immune system unrelated to inhibition of the human immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major histocompatibility complex class I restricted presentation of several viral antigens at therapeutically relevant concentrations (5 microM). In search of a molecular target we found that Ritonavir inhibited the chymotrypsin-like activity of the proteasome whereas the tryptic activity was enhanced. In this study we kinetically analyzed how Ritonavir modulates proteasome activity and what consequences this has on cellular functions of the proteasome. Ritonavir is a reversible effector of proteasome activity that protected the subunits MB-1 (X) and/or LMP7 from covalent active site modification with the vinyl sulfone inhibitor(125)I-NLVS, suggesting that they are the prime targets for competitive inhibition by Ritonavir. At low concentrations of Ritonavir (5 microM) cells were more sensitive to canavanine but proliferated normally whereas at higher concentrations (50 microM) protein degradation was affected, and the cell cycle was arrested in the G(1)/S phase. Ritonavir thus modulates antigen processing at concentrations at which vital cellular functions of the proteasome are not yet severely impeded. Proteasome modulators may hence qualify as therapeutics for the control of the cytotoxic immune response.</dcterms:abstract>
    <dc:contributor>Schmidtke, Gunter</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-01T10:45:06Z</dc:date>
    <dcterms:title>How an inhibitor of the HIV-I protease modulates proteasome activity</dcterms:title>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dc:contributor>Giuli, Rita de</dc:contributor>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22236"/>
    <dc:creator>Groll, Michael</dc:creator>
    <dcterms:bibliographicCitation>The journal of biological chemistry : JBC ; 274 (1999), 50. - S. 35734-35740</dcterms:bibliographicCitation>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-01T10:45:06Z</dcterms:available>
    <dc:contributor>Holzhütter, Hermann-Georg</dc:contributor>
    <dc:language>eng</dc:language>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Diese Publikation teilen